Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ:COSM) has officially launched its U.S. operations with the introduction of its Sky Premium Life brand, targeting the lucrative $164 billion nutraceuticals market. The company has started sales of its flagship product, Sky Premium Life NOOR Collagen, crafted from premium marine collagen tripeptide, aimed at enhancing skin and joint health. All products are manufactured in FDA-registered, GMP-certified facilities within the U.S., a strategy designed to ensure regulatory compliance while minimizing tariff and logistical challenges.
CEO Greg Siokas expressed enthusiasm about the promising early sales of NOOR Collagen, which is projected to generate over $12 million annually. Cosmos Health expects gross margins of around 75%, indicating a strong potential for cash flow as it plans to expand its U.S. product offerings to cater to rising consumer demand for health and wellness solutions.
The nutraceuticals market in the U.S. is projected to grow at a compound annual growth rate (CAGR) of 6.2% through 2030, driven by increasing health consciousness and demand for natural wellness products. Cosmos Health aims to capitalize on this trend to solidify its position as a key player in the industry.
With a diversified portfolio that includes several proprietary pharmaceutical and nutraceutical brands, Cosmos Health has established itself as a vertically integrated global healthcare group. The U.S. launch is a significant milestone in the company's expansion strategy, reflecting its commitment to offering scientifically validated, high-efficacy formulations. The Sky Premium Life NOOR Collagen is merely the first in a series of planned product introductions, indicating a focused effort to penetrate the largest market for nutraceuticals globally.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ: COSM) has initiated an encouraging chapter in its growth strategy by launching its Sky Premium Life brand into the lucrative U.S. nutraceuticals market, projected to be worth $164 billion. The company's focus on U.S. operations is amplified by its commitment to local manufacturing in GMP-certified facilities, ensuring compliance and quality while mitigating cross-border risks.
The introduction of Sky Premium Life NOOR Collagen, a premium marine collagen product, signals Cosmos Health's strategic entry into a sector characterized by increasing consumer demand for health and wellness solutions. With anticipated gross margins of 75% and projected annual revenues of over $12 million from NOOR Collagen alone, the company's operational forecast is promising. This strong potential for cash flow underscores the financial viability of its U.S. initiatives.
The nutraceutical market is experiencing robust growth, driven by heightened health awareness and consumer preference for natural wellness products. Cosmos’s strategic entry aligns well with this trend, particularly as both aging and younger demographics prioritize wellness. As the company expands its product portfolio within the U.S., it stands to gain from growing demand in a market that is evolving toward scientifically validated health solutions.
However, while the outlook appears favorable, investors should remain cautious. The nutraceuticals space is increasingly competitive, and success depends on effective brand differentiation and consumer trust. Moreover, the company must manage risks associated with regulatory compliance and operational scalability.
For investors considering Cosmos Health, it presents a compelling opportunity to tap into a burgeoning market, albeit with standard risks associated with the healthcare sector. Watching how effectively the company rolls out its U.S. strategy and expands its offerings will be crucial in assessing its long-term growth trajectory and investment potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its proprietary Sky Premium Life food supplements brand.
All Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.
Sales are already underway for Sky Premium Life NOOR Collagen, a proprietary product formulated with premium marine collagen tripeptide, currently available in capsule form and featuring a clinically validated formula designed to support skin and joint health.
The Company anticipates strong gross margins of approximately 75% and significant cash flow generation from its Sky Premium Life U.S. operations. NOOR Collagen alone is projected to generate more than $12 million in annualized revenue, with additional growth expected as the Company introduces new products and expands its Sky Premium Life portfolio in the U.S. to meet strong consumer demand.
According to Grand View Research , the U.S. nutraceuticals market was valued at $163.7 billion in 2024 and is projected to grow at a CAGR of 6.2% through 2030. Growth is fueled by rising health awareness, demand for natural wellness solutions, and increasing consumer interest in products that support immunity, gut health, cognition, and energy. With both aging and younger demographics proactively investing in wellness, the U.S. remains the world’s largest and most influential nutraceuticals market.
Greg Siokas, CEO of Cosmos Health, stated: "We are very pleased to officially commence U.S. operations with the launch of Sky Premium Life NOOR. Early sales momentum is encouraging, and we expect a significant revenue boost from our U.S. operations. This launch marks an important milestone in Cosmos’ expansion strategy as we establish our footprint in the world’s largest nutraceuticals market, supported by local manufacturing capabilities. Sky Premium Life NOOR Collagen is the first step in a series of planned U.S. product introductions that reflect our commitment to scientifically validated, high-efficacy formulations. We expect our U.S. business to become a key growth driver, reinforcing Cosmos’ position as a global healthcare innovator.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company’s expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company’s plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that the Facility will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company’s planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7277e15-9fd5-4ad2-8c62-d116146556dc
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
How does Cosmos Holdings Inc. COSM plan to navigate the competitive landscape of the U.S. nutraceuticals market as it launches its Sky Premium Life brand and NOOR Collagen?
What specific regulatory considerations does Cosmos Holdings Inc. COSM face now that its U.S. operations are underway, especially regarding local manufacturing?
How does Cosmos Holdings Inc. COSM intend to leverage its vertical integration to optimize profit margins and cash flow from its U.S. operations?
Can Cosmos Holdings Inc. COSM provide insights on its upcoming product introductions for the Sky Premium Life brand, and how these align with projected market growth trends?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
3.23% G/L:
$0.2586 Last:
675,836 Volume:
$0.2525 Open:
